Rare disease pharmas could benefit from FDA guidance to accelerate development
Source: SeekingAlpha
2026-02-23 14:34:32 ET
More on CRISPR Therapeutics, Intellia Therapeutics
- Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward
- CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
- Crispr: Emphasis Shifts To Cardiovascular Pipeline Amid Slow Casgevy Launch
- Insider trades: Merck, Intel, Micron among notable names
- Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug
Read the full article on Seeking Alpha
For further details see:
Rare disease pharmas could benefit from FDA guidance to accelerate development
CRISPR Therapeutics AG
NASDAQ: CRSP
CRSP Trading
4.34% G/L:
$57.64 Last:
488,540 Volume:
$55.59 Open:
CRSP Latest News
March 04, 2026 01:43:00 pm
Forget CRISPR Therapeutics: This Gene?Editing Player Already Boasts the Profits It Dreams Of
February 25, 2026 09:00:00 am
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
CRSP Stock Data
$4,723,079,547
91,202,323
0.18%
215
N/A
Biotechnology & Life Sciences
Healthcare
CH
Zug
